Towards better decision making in growth hormone therapy.
Controlled clinical trials are not always possible or warranted. Other sources of data include observational studies, meta-analyses, expert opinions, subjective judgements, and mathematical/statistical models developed from large databases. Decision analysis is presented as a preferred methodology for analysis in situations of uncertainty, in combination with cost-benefit and cost-effectiveness analyses. Special emphasis is given to quality-of-life considerations in growth hormone (GH) therapy and ways to measure it and express patient preferences.
Ben-Gurion University of the Negev, Beer-Sheva, Israel.
J S
JS
Pliskin
D001827:Body Height; D002648:Child; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D019992:Databases as Topic; D003657:Decision Making; D020000:Decision Support Systems, Clinical; D019317:Evidence-Based Medicine; D006130:Growth Disorders / Q000188:drug therapy* / Q000523:psychology; D019382:Human Growth Hormone / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D020407:Internet; D015233:Models, Statistical; D011788:Quality of Life; D014481:United States
D019382:Human Growth Hormone